Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

GUTS

Fractyl Health Inc.

May 24 • 04:00PM ET

7.46

Dollar change -0.10
Percentage change -1.32	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF SCHA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	63.08%	Shs Outstand	47.90M	Perf Week	5.67%
Market Cap	357.33M	Forward P/E	-	EPS next Y	-2.56	Insider Trans	5.10%	Shs Float	17.68M	Perf Month	11.01%
Income	-	PEG	-	EPS next Q	-0.46	Inst Own	29.48%	Short Float	16.61%	Perf Quarter	-1.84%
Sales	-	P/S	-	EPS this Y	95.61%	Inst Trans	-	Short Ratio	9.87	Perf Half Y	-
Book/sh	1.76	P/B	4.24	EPS next Y	-28.39%	ROA	-	Short Interest	2.94M	Perf Year	-
Cash/sh	2.54	P/C	2.93	EPS next 5Y	-	ROE	-	52W Range	5.75 - 14.50	Perf YTD	-41.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-126.07%	ROI	-	52W High	-48.55%	Beta	-
Dividend TTM	-	Quick Ratio	9.37	Sales past 5Y	0.00%	Gross Margin	-	52W Low	29.74%	ATR (14)	0.52
Dividend Ex-Date	-	Current Ratio	9.38	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	58.53	Volatility	6.81% 6.82%
Employees	-	Debt/Eq	0.72	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	22.00
Option/Short	No / Yes	LT Debt/Eq	0.68	EPS Q/Q	66.90%	Payout	-	Rel Volume	0.36	Prev Close	7.56
Sales Surprise	-	EPS Surprise	100.00%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	297.62K	Price	7.46
SMA20	11.03%	SMA50	8.74%	SMA200	-2.02%	Trades		Volume	105,818	Change	-1.32%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-24	Initiated	Evercore ISI	Outperform
Feb-27-24	Initiated	Morgan Stanley	Overweight	$18
Feb-27-24	Initiated	BofA Securities	Buy	$26

May-20-24 06:00AM	Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 2024 (GlobeNewswire)
May-13-24 08:56PM	GUTS Stock Earnings: Fractyl Health Beats EPS for Q1 2024 (InvestorPlace)
04:00PM	Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
11:41AM	Fractyl Health Says New Revita Data Show Sustained Weight Loss, Glucose Control in Type 2 Diabetes (MT Newswires)
06:00AM	Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) (GlobeNewswire)
06:00AM	Loading…
May-08-24 06:00AM	Fractyl Health to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-07-24 06:00AM	Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 (GlobeNewswire)
Apr-30-24 08:38AM	Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting (GlobeNewswire)
Apr-17-24 03:10PM	The 3 Most Volatile Stocks for Short-Term Traders: April 2024 (InvestorPlace)
Apr-02-24 08:00AM	Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes (GlobeNewswire) -9.53%
Apr-01-24 07:00AM	Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
06:00AM	Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs (GlobeNewswire)
Mar-12-24 02:06PM	UPDATE -- Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire) -10.34%
08:38AM	Fractyl Health Announces New Results From Its Rejuva Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity (GlobeNewswire)
Mar-03-24 01:13PM	Analysts Bet Big on These Beaten-Down IPO Stocks (TipRanks)
08:38AM	Loading…
Feb-20-24 08:38AM	Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita Pivotal Clinical Trials (GlobeNewswire)
Feb-01-24 08:08PM	Fractyl Health Announces Pricing of Initial Public Offering (GlobeNewswire)

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Elia Marc	Director	Feb 06 '24	Buy	15.00	466,666	6,999,990	1,856,117	Feb 08 04:32 PM
CVF, LLC	10% Owner	Feb 06 '24	Buy	15.00	333,333	4,999,995	4,673,870	Feb 06 08:39 PM
Mithril LP	10% Owner	Feb 06 '24	Buy	15.00	333,333	4,999,995	1,251,900	Feb 08 04:35 PM
Royan Ajay	Director	Feb 06 '24	Buy	15.00	333,333	4,999,995	1,251,900	Feb 08 04:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GUTS

Fractyl Health Inc.

Upgrade your FINVIZ experience